Alvogen

Global Nephroblastoma Treatment Market Report 2022: Increasing R&D Activities Driving Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Martedì, Novembre 8, 2022
Health, Pharmaceutical, Organization, Wilms' tumor, Oncology, Sun Pharma, Pediatrics, Nausea, Industry, Dactinomycin, American Journal of Clinical Oncology, Swelling, Patient, MD, Department, CAGR, Benign tumor, Merck & Co., Kidney, City, Etoposide, Vincristine, Nephrectomy, Cyclophosphamide, Fever, Journal, Alvogen, US, Histology, Region, Carboplatin, Pfizer, Stomach, Merck, Pain scale, Market share, RCC, Neoplasm, Marketing, Research, Constipation, Medical imaging, Pharmaceutical industry

The "Nephroblastoma Treatment Market, by Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nephroblastoma Treatment Market, by Type, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Nephroblastoma, also known as Wilms tumor, is the most prevalent kind of renal cancer among pediatrics.
  • The most typical childhood abdominal cancer, wilms tumor, often manifests between the ages of 3 and 5.
  • Increasing research and development activities by various organizations and researchers to develop treatment options for nephroblastoma are expected to drive the market growth over the forecast period.

Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company’s Proposed Generic to Xifaxan® for IBS-D

Retrieved on: 
Giovedì, Agosto 11, 2022
Health, Pharmaceutical, Brand, IBS-D, Diarrhea, NASDAQ, Patient, Pharmaceutical industry, Alvogen

Alvogen, a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products, announced today a favorable district court ruling on multiple patents related to the companys proposed generic to Xifaxan, a treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults.

Key Points: 
  • Alvogen, a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products, announced today a favorable district court ruling on multiple patents related to the companys proposed generic to Xifaxan, a treatment for irritable bowel syndrome with diarrhea (IBS-D) in adults.
  • We are extremely pleased with the district courts decision, which brings us one step closer to bringing a more affordable alternative to patients taking Xifaxan for IBS-D, said Robert Wessman, Chairman of Alvogen.
  • Alvogen is a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products for the US market.
  • The company has a diverse portfolio and pipeline that includes both branded and generic products across various dosage forms.

Direct Relief Provides More Than 650 Tons of Medical Aid to Ukrainians Since War's Start

Retrieved on: 
Lunedì, Giugno 6, 2022
MSD, Company, Janssen Pharmaceuticals, Merck Group, MOH, Multimedia, Emergency service, AbbVie, World Bank, ICU Medical, Fortnite, AstraZeneca, COVID-19, Foundation, Ajanta Pharma, IOM, Direct Relief, Merck & Co., Medtronic, Device file, UNICEF, Health, UNHCR, Takeda Pharmaceutical Company, Mercy Corps, LifeScan, Teva Pharmaceuticals, Organization, Antidote, Baxter International, Hospital, Alvogen, GSK, Eli Lilly and Company, California Governor's Office of Emergency Services, McKesson Corporation, Sanofi, World, Amgen, Food, United Nations, Health care, Novo Nordisk, Refugee, Insulin, Water, Pharmacy, Epic Games, Person, Pharmaceutical industry, Health insurance, Online gambling, Apotex, Bayer, Unilever, Medicine, Pfizer

SANTA BARBARA, Calif., June 6, 2022 /PRNewswire/ -- In the three months since Russian forces began their invasion of Ukraine on Feb. 24, Direct Relief has been one of the largest charitable providers of medical aid to Ukraine, delivering more than 650 tons (1.3 million pounds) of medicines and supplies with a wholesale value of more than $315 million.

Key Points: 
  • The medical aid includes 101 million defined daily doses of medicine, including antibiotics, insulin, mental health medicines, cancer treatments, chemical weapons antidotes, COVID-19 treatment and more.
  • Direct Relief has also provided over $14.7 million in direct financial assistance to other organizations in the region.
  • "Direct Relief's three-month report on humanitarian assistance to Ukraine reflects the generosity of an extensive private coalition of individuals and businesses globally," said Direct Relief President and CEO Thomas Tighe.
  • In addition to the provision of medical material and financial aid in response to the crisis, Direct Relief has been a critical supplier of information.

Global Suboxone Market Size, Share, Outlook, and Opportunity Analysis Report 2022-2030 - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Maggio 19, 2022
Health, Pharmaceutical, Sun Pharma, Laboratory, Market share, Centers for Disease Control and Prevention, Buprenorphine, Pain management, Region, Naloxone, Novartis, US, Marketing, Research, Industry, Indivior, Buprenorphine/naloxone, Alvogen, Chronic pain, Center, CAGR, Growth, Prevalence, Renewable energy, Pharmaceutical industry

The "Global Suboxone Market by Type, Formulation, Distribution Channel, and Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Suboxone Market by Type, Formulation, Distribution Channel, and Region - Size, Share, Outlook, and Opportunity Analysis, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • Suboxone is a prescription opioid medication that is used to inhibit the effects of opioid medications, such as pain relief, which can lead to opioid dependence.
  • The increasing product launches for suboxone is expected to drive the growth of global suboxone market over the forecast period.
  • Furthermore, increasing prevalence of chronic pain is expected to drive the growth of global suboxone market over the forecast period.

Robert Wessman-led Aztiq completes $500 million transaction in an alliance with Innobic to create an international pharma powerhouse

Retrieved on: 
Martedì, Maggio 10, 2022
Board, Innovation, Senior, Consortium, Patient, Founder, GX, CVC Capital Partners, CEO, TWSE, PTT, Research, Seemabaddha, Acquisition, Motor vehicle, Fine chemical, Pharmaceutical industry, Lotus, Pharma, Alvogen, ASEAN

Key shareholders in Alvogen include CVC Capital Partners and Temasek Holdings of Singapore, as well as Aztiq.

Key Points: 
  • Key shareholders in Alvogen include CVC Capital Partners and Temasek Holdings of Singapore, as well as Aztiq.
  • Aztiq is led by Robert Wessman, who will continue to serve as Chairman of the Board of Lotus and Adalvo.
  • Rbert Wessman, has led over 50 strategic acquisitions and partnerships and established operations in over 60 countries.
  • Wessman, alongside his seasoned team in Aztiq, continues to successfully launch and scale both industry-leading generic pharmaceutical and biosimilar companies all over the world.

Robert Wessman-led Aztiq completes $500 million transaction in an alliance with Innobic to create an international pharma powerhouse

Retrieved on: 
Martedì, Maggio 10, 2022
Board, Innovation, Senior, Consortium, Patient, Founder, GX, CVC Capital Partners, CEO, TWSE, PTT, Research, Seemabaddha, Acquisition, Motor vehicle, Fine chemical, Pharmaceutical industry, Lotus, Pharma, Alvogen, ASEAN

Key shareholders in Alvogen include CVC Capital Partners and Temasek Holdings of Singapore, as well as Aztiq.

Key Points: 
  • Key shareholders in Alvogen include CVC Capital Partners and Temasek Holdings of Singapore, as well as Aztiq.
  • Aztiq is led by Robert Wessman, who will continue to serve as Chairman of the Board of Lotus and Adalvo.
  • Rbert Wessman, has led over 50 strategic acquisitions and partnerships and established operations in over 60 countries.
  • Wessman, alongside his seasoned team in Aztiq, continues to successfully launch and scale both industry-leading generic pharmaceutical and biosimilar companies all over the world.

BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance

Retrieved on: 
Giovedì, Gennaio 20, 2022
Face, Patient, News, Alvogen, Buprenorphine, Pharmacy, COVID-19, Migraine, Total, LAO, Growth, NASDAQ, CEO, Physician, GLOBE, Chronic pain, Headache, CIII, TRX, Pain, Marketing, Company, CFO, Patent, FDA, Neurology, Omicron, III, COVID, Kerosene, Lithium, Pharmaceutical industry, Animal, Fine chemical, EBITDA

RALEIGH, N.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced it expects 2021 total Company net revenues and BELBUCA® (buprenorphine buccal film) net sales to achieve the high end of its previous guidance range, and 2021 EBITDA to come in above its prior guidance range.

Key Points: 
  • For the full year 2021, BELBUCA TRx volumes were up a solid 8.8% year-over-year despite headwinds reported earlier this year.
  • Symproic (naldemedine) similarly achieved an all-time high 13.0% TRx share and volumes of 19,000 for Q4 2021, an increase of 5.3% year-over-year.
  • Mr. Bailey added, Moreover, the use of buprenorphine for chronic pain continued to grow 8.6% year-over-year in 2021.
  • Total Company Net Revenue for 2021 is expected to be in the range of $165-$167 million, compared to previous guidance of $162-$167 million.

BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032

Retrieved on: 
Lunedì, Dicembre 20, 2021
GLOBE, ANDA, Chronic pain, Form 10-K, Pain, Physician, John Davis (U.S. district court judge), CEO, Marketing, Security (finance), U.S. Securities and Exchange Commission, COVID-19, NASDAQ, Dechert, Risk, Private Securities Litigation Reform Act, Annual report, Patent, Migraine, District court, New Drug Application, Opioid, LLP, Alvogen, Patient

The opinion by the trial judge upholds the validity of claims in BDSIs patents 8,147,866 (the 866 patent), which expires in 2027, and 9,901,539 (the 539 patent), which expires in 2032.

Key Points: 
  • The opinion by the trial judge upholds the validity of claims in BDSIs patents 8,147,866 (the 866 patent), which expires in 2027, and 9,901,539 (the 539 patent), which expires in 2032.
  • Accordingly, BDSI expects market exclusivity of BELBUCA against Alvogen until 2032.
  • We are pleased with the Courts decision and look forward to continuously supplying BELBUCA to chronic pain patients, stated Jeff Bailey, CEO of BDSI.
  • BioDelivery Sciences International, Inc.(NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions.

Adalvo recognized as one of the Best Workplaces for 2021

Retrieved on: 
Martedì, Novembre 30, 2021
Patient, Corporate communication, Industry, Achievement, Choice, Program, COVID-19, Workplace, Twitter, Culture, Organization, The Last Best Place, Alvogen, LinkedIn, Employment, Certification, Growth, Management

LONDON, Nov. 30, 2021 /CNW Telbec/ - Adalvo, one of the leading B2B global pharmaceutical companies, with commercial partnerships in more than 100 countries, have been certified as one of the Best Places to Work for 2021 !

Key Points: 
  • LONDON, Nov. 30, 2021 /CNW Telbec/ - Adalvo, one of the leading B2B global pharmaceutical companies, with commercial partnerships in more than 100 countries, have been certified as one of the Best Places to Work for 2021 !
  • This is the first time that Adalvo has achieved this certification, and credits the achievement to employees' commitment to excellence, and shared values.
  • The certification is based on a rigorous assessment methodology and a framework that reflects the very latest in workplace trends.
  • Adalvo has scored outstandingly in diversity & inclusion, fostering equity in the workplace, creating a flexible, transparent and supportive environment.

Róbert Wessman Inaugurates New London Offices of His Private Equity Fund Aztiq

Retrieved on: 
Giovedì, Novembre 18, 2021
Biotechnology, Commercial Building & Real Estate, Construction & Property, REIT, Professional Services, Other Health, Health, General Health, Pharmaceutical, Other Professional Services, Other Construction & Property, Alvo, CEO, Transport, Partnership, Chief executive officer, Investment, Alvogen, Airport, Interior design, Fine chemical, Aztiq, Róbert Wessman, AZTIQ, RóBERT WESSMAN

Rbert Wessman, the founder and principal shareholder in the Alvo group of leading pharmaceutical companies, formally opened the new London offices of his investment fund, Aztiq, at a ceremony in Hammersmith on 18 November 2021.

Key Points: 
  • Rbert Wessman, the founder and principal shareholder in the Alvo group of leading pharmaceutical companies, formally opened the new London offices of his investment fund, Aztiq, at a ceremony in Hammersmith on 18 November 2021.
  • Rbert Wessman commented, It is a great pleasure to open the doors of our new offices to our colleagues and partners.
  • About Aztiq: Aztiq is a long-term investment fund led by Robert Wessman.
  • About Rbert Wessman: Rbert Wessman is Chairman & CEO at Alvogen, and founder and Chairman at Alvotech.